Ufp Technologies Inc
UFPT Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What Ufp Technologies Inc does
No business description yet.
- Legal name
- UFP TECHNOLOGIES INC
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 27, 2026
- Accession Β· CIK
- 0001628280-26-012816
0000914156
Revenue and margins
Ufp Technologies Inc had $603M of revenue in fiscal 2025, up 19.5% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 25.9% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Ufp Technologies Inc returned β to shareholders in fiscal 2025. The diluted share count rose 0.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably Ufp Technologies Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $11.1M | $4.5M | $5.3M | $13.5M | $20.3M |
| Debt incl. finance leases | $75.3M | $55.2M | $32.2M | $189M | $135M |
| Net debt / EBITDA | 2.2x | 0.8x | 0.4x | 1.8x | 1.0x |
| Debt / equity | 0.4x | 0.2x | 0.1x | 0.6x | 0.3x |
| Interest coverage | 544.1x | 20.1x | 15.8x | 10.0x | 9.4x |
| Current ratio | 2.3x | 2.1x | 2.5x | 2.6x | 2.7x |
| Quick ratio | 1.4x | 1.1x | 1.3x | 1.4x | 1.5x |
| Total assets | $334M | $378M | $404M | $629M | $655M |
| Total liabilities | $140M | $141M | $118M | $286M | $231M |
| Shareholders' equity | $194M | $238M | $286M | $343M | $424M |
| Net debt (β = net cash) | $64.2M | $50.8M | $26.9M | $176M | $115M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 8 | 5 / 8 | 7 / 8 | 4 / 8 | 2 / 9 | 6 / 9 | 7 / 9 | 5 / 9 | 7 / 9 |
| Accruals ratio | β1.0% | β6.2% | β4.3% | β6.1% | β6.0% | 0.6% | 6.8% | 0.9% | β1.5% | β3.7% |
| Altman Z'' | 13.96 | 14.92 | 6.83 | 10.77 | 11.77 | 4.41 | 5.55 | 6.90 | 4.95 | 6.00 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $146M | $148M | $190M | $198M | $179M | $206M | $354M | $400M | $504M | $603M |
| Gross profit | $34.7M | $35.5M | $48.3M | $54.0M | $44.7M | $51.1M | $90.3M | $112M | $147M | $170M |
| Research and development | $1.3M | $5.0M | $10.5M | $8.8M | $8.2M | $8.5M | $9.3M | $7.2M | $10.4M | $8.6M |
| Operating income | $12.2M | $11.7M | $19.6M | $24.7M | $16.7M | $21.2M | $55.4M | $57.7M | $80.9M | $92.3M |
| Interest expense | $0.1M | $0.1M | $1.3M | $0.7M | $0.1M | $0.0M | $2.8M | $3.6M | $8.1M | $9.8M |
| Pretax income | $12.3M | $11.9M | $18.4M | $23.6M | $16.3M | $21.2M | $52.7M | $53.9M | $73.0M | $82.5M |
| Income tax | $4.3M | $2.6M | $4.1M | $3.9M | $2.9M | $5.3M | $10.9M | $9.0M | $14.0M | $14.2M |
| Net income | $8.0M | $9.2M | $14.3M | $19.8M | $13.4M | $15.9M | $41.8M | $44.9M | $59.0M | $68.3M |
| Diluted EPS | $1.10 | $1.26 | $1.93 | $2.63 | $1.77 | $2.09 | $5.45 | $5.83 | $7.58 | $8.75 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $9.3M | $17.5M | $21.3M | $31.2M | $25.0M | $14.3M | $17.7M | $41.3M | $66.6M | $91.9M |
| Capital expenditure | $7.2M | $10.4M | $5.4M | $5.8M | $4.4M | $5.4M | $13.8M | $10.5M | $9.7M | β |
| Free cash flow | $2.1M | $7.1M | $15.9M | $25.5M | $20.7M | $8.9M | $4.0M | $30.8M | $56.9M | β |
| Depreciation and amortization | $5.6M | $5.6M | $7.8M | $8.2M | $8.3M | $8.4M | $11.9M | $11.4M | $14.7M | $19.2M |
| Stock-based compensation | $1.1M | $1.1M | $1.2M | $1.6M | $1.8M | $2.4M | $3.2M | $4.6M | $6.8M | $8.9M |
| Acquisitions | β | β | $77.0M | $0.0M | $0.0M | $96.2M | $20.7M | $0.0M | $197M | $14.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $31.4M | $38.0M | $3.2M | $3.7M | $24.2M | $11.1M | $4.5M | $5.3M | $13.5M | $20.3M |
| Total debt | $0.9M | β | $25.1M | β | $0.0M | $75.0M | $55.0M | $32.0M | $189M | $135M |
| Finance lease liabilities | β | β | $0.0M | β | $0.1M | $0.3M | $0.2M | $0.2M | $0.1M | $0.0M |
| Current assets | $69.8M | $75.1M | $55.6M | $53.3M | $71.9M | $87.3M | $116M | $145M | $195M | $201M |
| Current liabilities | $9.6M | $9.9M | $20.7M | $16.8M | $15.1M | $38.8M | $56.0M | $58.2M | $76.3M | $74.9M |
| Inventory | $14.2M | $12.9M | $19.6M | $18.3M | $18.6M | $33.4M | $53.5M | $70.2M | $87.5M | $86.9M |
| Property and equipment, net | $48.5M | $53.7M | $57.7M | $56.7M | $53.8M | $56.6M | $58.1M | $62.1M | $70.6M | $79.1M |
| Goodwill | $7.3M | $7.3M | $51.8M | $51.8M | $51.8M | $108M | $113M | $113M | $190M | $197M |
| Intangible assets | $0.3M | β | $22.2M | $21.0M | $19.7M | $67.6M | $68.4M | $64.1M | $144M | $141M |
| Total assets | $128M | $138M | $190M | $189M | $203M | $334M | $378M | $404M | $629M | $655M |
| Total liabilities | $14.9M | $14.5M | $49.1M | $26.8M | $26.3M | $140M | $141M | $118M | $286M | $231M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $113M | $124M | $140M | $162M | $177M | $194M | $238M | $286M | $343M | $424M |
| Margins | ||||||||||
| Gross margin | 23.7% | 24.0% | 25.4% | 27.2% | 24.9% | 24.8% | 25.5% | 28.1% | 29.1% | 28.3% |
| Operating margin | 8.4% | 7.9% | 10.3% | 12.5% | 9.3% | 10.3% | 15.7% | 14.4% | 16.0% | 15.3% |
| EBITDA margin | 12.2% | 11.7% | 14.4% | 16.6% | 13.9% | 14.4% | 19.0% | 17.3% | 19.0% | 18.5% |
| Net margin | 5.5% | 6.2% | 7.5% | 10.0% | 7.5% | 7.7% | 11.8% | 11.2% | 11.7% | 11.3% |
| FCF margin | 1.4% | 4.8% | 8.3% | 12.8% | 11.5% | 4.3% | 1.1% | 7.7% | 11.3% | β |
| Returns | ||||||||||
| Return on capital | 9.6% | β | 9.4% | β | 9.0% | 6.2% | 15.2% | 15.4% | 12.6% | 14.2% |
| Return on capital employed | 10.3% | 9.1% | 11.6% | 14.4% | 8.9% | 7.2% | 17.2% | 16.7% | 14.6% | 15.9% |
| Return on equity | 7.0% | 7.8% | 10.8% | 13.1% | 7.9% | 8.6% | 19.3% | 17.2% | 18.8% | 17.8% |
| Return on assets | 6.2% | 6.9% | 8.7% | 10.4% | 6.8% | 5.9% | 11.7% | 11.5% | 11.4% | 10.6% |
| Return on tangible equity | 7.6% | 7.9% | 21.6% | 22.1% | 12.7% | 83.8% | 74.4% | 41.3% | 666.4% | 79.8% |
| Growth | ||||||||||
| Revenue growth | β | 1.2% | 28.8% | 4.2% | β9.6% | 15.0% | 71.5% | 13.1% | 26.1% | 19.5% |
| Net income growth | β | 15.6% | 55.4% | 38.0% | β32.3% | 18.8% | 163.1% | 7.5% | 31.3% | 15.8% |
| EPS growth | β | 14.5% | 53.2% | 36.3% | β32.7% | 18.1% | 160.8% | 7.0% | 30.0% | 15.4% |
| FCF growth | β | 237.5% | 124.2% | 60.1% | β18.8% | β57.0% | β55.5% | 678.1% | 84.6% | β |
| Share count change | β | 0.9% | 1.3% | 1.2% | 0.7% | 0.6% | 0.6% | 0.5% | 1.1% | 0.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β1.7x | β | 0.8x | β | β1.0x | 2.2x | 0.8x | 0.4x | 1.8x | 1.0x |
| Debt / equity | 0.0x | β | 0.2x | β | 0.0x | 0.4x | 0.2x | 0.1x | 0.6x | 0.3x |
| Interest coverage | 177.3x | 233.9x | 14.9x | 36.7x | 201.6x | 544.1x | 20.1x | 15.8x | 10.0x | 9.4x |
| Current ratio | 7.3x | 7.6x | 2.7x | 3.2x | 4.7x | 2.3x | 2.1x | 2.5x | 2.6x | 2.7x |
| Quick ratio | 5.8x | 6.3x | 1.7x | 2.1x | 3.5x | 1.4x | 1.1x | 1.3x | 1.4x | 1.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 4.9% | 7.0% | 2.9% | 2.9% | 2.4% | 2.6% | 3.9% | 2.6% | 1.9% | β |
| Stock comp / revenue | 0.7% | 0.7% | 0.6% | 0.8% | 1.0% | 1.2% | 0.9% | 1.2% | 1.4% | 1.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 5.0 | 7.0 | 4.0 | 2.0 | 6.0 | 7.0 | 5.0 | 7.0 |
| Altman Z'' | 14.0 | 14.9 | 6.8 | 10.8 | 11.8 | 4.4 | 5.6 | 6.9 | 4.9 | 6.0 |
| Accruals ratio | β1.0% | β6.2% | β4.3% | β6.1% | β6.0% | 0.6% | 6.8% | 0.9% | β1.5% | β3.7% |
Source: SEC EDGAR XBRL filings (CIK 0000914156). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.